IDP-121 is under clinical development by IDP Discovery Pharma and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IDP-121’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IDP-121 overview

IDP-121 is under development for the treatment of relapsed and refractory chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma, high-grade B cell lymphoma, multiple myeloma. It is a synthetic stapled peptide which acts by targeting Myc proto oncogene protein (MYC). The drug candidate is administered through intravenous route.

It was under development for the treatment of solid tumors.

IDP Discovery Pharma overview

IDP Discovery Pharma, is a drug discovery company that develops first-in-class medicines. The company is headquartered in Spain.

For a complete picture of IDP-121’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.